Authors are grateful for the support from the National Taiwan University (NTU) School of Pharmacy Endowment Fund in support of the Platform for Research and Inspiration in Regulatory Science. An article entitled “The impact of The Rare Disease and Orphan Drug Act in Taiwan” by Ning-Chun Hsiang, Weng-Foung Huang, Churn-Shiouh Gau, Teng-Wen Tsai, Lin-Chau Chang is published in the journal, Journal of Food and Drug Analysis, on 15 December 2021. The Rare Disease and Orphan Drug Act (the Act) was enacted in 2000 in Taiwan. In order to investigate the impact of the Act on the availability and use of orphan drugs in Taiwan, this study analyzed the official annual reports and documents. The Act increased the availability of orphan drugs in Taiwan. However, the soaring economic burden was noticed and was anticipated to aggravate. More communication and cooperation between stakeholders is critical in finding solutions for the long-term sustainability of the National Health Insurance system.
Authors are grateful for the support from the National Taiwan University (NTU) School of Pharmacy Endowment Fund in support of the Platform for Research and Inspiration in Regulatory Science.
Please click here for the original article.
感謝「臺大藥學發展永續基金計畫」對於國際藥政法規科學研究平台之支持，項甯珺、黃文鴻、高純琇、蔡騰文、張琳巧，以“The impact of The Rare Disease and Orphan Drug Act in Taiwan”為題之文章，已於2021年12月15日發表於Journal of Food and Drug Analysis期刊。臺灣於2000年公布施行「罕見疾病防治及藥物法」，為了解此法案對臺灣罕見疾病用藥之可取得性及使用情形的影響，本研究分析官方藥物年報及文件。此法案確實增加罕見疾病用藥之可取得性，但急遽增長之財政負擔有待利益相關人更多之溝通與合作，為全民健康保險體系尋得永續經營的解決之道。
請參考原始文獻。
